Hutchison Medipharma Limited
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Recorded as renamed to Hutchmed Limited (2022)
6
Ending by 2030
Nov 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Substituted Piperazines as BTK Inhibitors (US 11,655,254) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor (US 10,512,645) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor (US 11,896,592) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Novel Imidazopyridazine Compounds and Their Use (US 10,611,777) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,946,249 | Compound, Certain Novel Forms Thereof, Pharmaceutical Compositions Thereof and Methods for Preparation and Use In force · Low confidence | In force | Low confidence | |
| US 8,507,487 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 8,987,269 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 9,956,218 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 10,512,645 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 10,946,014 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 11,896,592 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence | |
| US 10,052,330 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,434,726 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,701,680 | Pyrimidine and pyridine compounds and their usage In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 28: 6 patents in force now held by others · 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 2 abandoned · 8 no status recorded